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RemyelinationConsidering the worldwide incidence of well characterized demyelinating disorders such as
Multiple Sclerosis (MS) and the increasing number of pathologies recently found to involve
hypomyelinating factors such as micronutrient deﬁcits, elucidating the molecular basis of central
nervous system (CNS) demyelination, remyelination and hypomyelination becomes essential to
the development of future neuroregenerative therapies. In this context, this review discusses novel
ﬁndings on the contribution of galectin-3 (Gal-3), transferrin (Tf) and iron to the processes of myeli-
nation and remyelination and their potentially positive regulation of oligodendroglial precursor cell
(OPC) differentiation. Studies were conducted in cuprizone (CPZ)-induced demyelination and iron
deﬁciency (ID)-induced hypomyelination, and the participation of glial and neural stem cells
(NSC) in the remyelination process was evaluated by means of both in vivo and in vitro assays on
primary cell cultures.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Oligodendrocytes (OLG) are glial cells in charge of myelin pro-
duction in the central nervous system (CNS) and thus play a key
role in demyelinating disorders, among which Multiple Sclerosis
(MS) appears to exhibit the highest incidence [1–3]. Therefore,
among the various trophic factors which have been identiﬁed to
support OLG maturation and proliferation, e.g. ﬁbroblast growth
factor (FGF), platelet-derived growth factor (PDGF), insulin-like
growth factor 1 (IGF-1) and thyroid hormones [4–6], this review
will focus on the roles of galectin-3 (Gal-3), transferrin (Tf) and
iron in OLG differentiation.
OLG are known to produce most CNS Tf [7,8] and their matura-
tion is directly related with the fact that the brain is the only organ
in which Tf mRNA expression increases after birth, compellingevidence of Tf importance [9]. In this context, numerous studies
published by our group since 1994 have attempted to determine
whether Tf has an iron-independent trophic effect on myelin pro-
duction. A critical question in assessing Tf trophic actions is
whether apotransferrin (aTf, iron-free Tf) acquires iron once it is
injected in vivo or from the cell culture media. Iron ubiquity and
its high afﬁnity for aTf suggest that it would rapidly bind to
injected aTf even in small concentrations [10], although evidence
seems to establish that it is aTf, and not iron binding to Tf, that
has pro-differentiating effects [11].
On the basis of the key role of iron in OLG maturation and mye-
lin production, and considering that hypomyelination as a conse-
quence of iron deﬁcits and the associated neurological sequelae
persist long after these deﬁcits have been corrected [12–14], stud-
ies in our lab targeted the possible ameliorating effects of an
intracranial injection (ICI) of aTf in iron deﬁciency (ID) conditions,
with results rendering a partial correction of myelin deﬁcits.
Subsequent assays in cultures of OLG isolated from control and
ID animals revealed a smaller number of differentiated cells in
ID conditions, followed by a partial recovery upon aTf treatment
[15].
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working on molecules apparently working as external signals in
OLG differentiation, i.e. galectins (Gals), which are well known
within the immune system [16], but not as widely characterized
in connection with the CNS. We have identiﬁed an essential role
for Gal–glycan interactions in regulating OLG differentiation
leading to the control of myelin integrity and function and, in
particular, we have assessed Gal-3 potential role in modulating
neuroimmune processes [17].
2. Cuprizone and demyelination
The cuprizone (CPZ) model has been described as a useful tool
to study demyelination and remyelination phenomena [18], with
advantages such as easy reproduction and low mortality rates
[19]. In mouse models, a CPZ diet has been shown to produce
demyelination and OLG damage in the CNS – particularly in the
corpus callosum (CC), [20] – without compromising other cell
types [21–23], while its termination brings about spontaneous
and almost complete remyelination in a matter of weeks
[21,24,25].
Although Cammer [26] showed CPZ-induced cell damage in
OLG-enriched glial cell cultures and mixed glial cell cultures from
neonatal rat brains, the demyelinating effects of CPZ in vivo have
proven to be very effective in mice but not in rats [20]. Rats and
guinea pigs exposed to CPZ have been reported to show spongi-
form encephalopathy [27] but not demyelination. In turn, weaning
Wistar rats fed a diet containing 0.5–2% CPZ have exhibited intra-
myelinic edema and OLG mitochondrial enlargement, among other
abnormalities, in different areas of the cerebellum [28]. With these
two exceptions, our group has pioneered the description of CPZ
effects on myelin in rats [29].
Similarly to what has been described in mice [20], CPZ demyeli-
nation in rats stops upon termination of CPZ administration and is
followed by spontaneous remyelination. Two weeks after toxin
withdrawal, myelin yields increase substantially and myelin pro-
tein, phospholipid and galactolipid contents recover, although still
remaining well below control values. A suitable model to evaluate
remyelination strategies in rodents without involving the adaptive
immune system, CPZ-induced demyelination by OLG degeneration
in white and gray matter is accompanied by reactive gliosis [30–
33], an increase in the number of resident microglia (MG) and, to
a lesser extent, a rise in the number of peripheral macrophages
[34]. In order to characterize the mechanism of CPZ-induced
demyelination, we used rat primary oligodendroglial cell cultures
and evaluated CPZ effects on cell viability, which was only signiﬁ-
cantly affected when either IFNc or TNFawere present. In addition,
in vivo experiments showed that the inhibition of microglial acti-
vation with minocycline prevented CPZ-induced demyelination.
Taken together, our results demonstrate an active role for micro-
glial cells in CPZ-induced oligodendroglial cell death and demyeli-
nation, through the production and secretion of pro-inﬂammatory
cytokines [35].
3. Demyelinating diseases and oligodendrocyte damage.
Endogenous sources of remyelination
Demyelination is deﬁned as the process governed by the loss of
myelin sheaths around neuronal axons and it is a consequence of
oligodendroglial dysfunction or death, which, if sustained in time,
inexorably leads to neuronal damage and neurodegeneration [36].
Among human demyelinating pathologies of the CNS, MS has a
mean age of onset in young adulthood and clinical neurodegener-
ative manifestations in motor, sensory and cognitive disability. MS
is considered a chronic autoimmune disease and is characterized
by the emergence of demyelination foci in different brain areas,accompanied by a marked inﬂammatory response with microglial
activation and astrogliosis [37]. Although the adaptive immune
system plays a leading role in the acute pathogenesis of MS in most
cases, primary oligodendropathy prevails in some patients [38,39].
An endogenous tissue response to CNS demyelination, remyelina-
tion tends to restore oligodendroglial population and myelin
sheaths and is detected at early stages of MS. However, the process
fails in the long run [40,41] and the pathological environment asso-
ciated with the disease prevents successful long-term myelin
recovery [42].
Much effort has been made lately in order to understand the
pathophysiological complexities that unfold during MS and atten-
tion has been drawn toward developing effective strategies to
stimulate myelin repair in the injured brain [43]. In this context,
although animal models do not completely recapitulate human
MS features, they continue to stand as useful tools for studying
remyelination processes in vivo. In CPZ-induced demyelination
models in rodents, several hormones such us thyroid hormones
[44–47], sex hormones [48–50] or different growth factors
[51–53] have been shown to stimulate myelin recovery. Despite
their effectiveness in promoting remyelination, the exact
mechanisms through which these factors trigger oligodendroglial
generation are still unresolved.
Remyelination could proceed by two alternative mechanisms
[54]: (a) a rapid response of local oligodendroglial precursor cells
(OPC), which undergo differentiation/oligodendroglial maturation
and (b) a process involving neural stem cell (NSC) activation and
neural progenitor cell (NPC) proliferation from a subventricular
zone (SVZ) niche, migration of progenitor cells toward damaged
brain areas and terminal oligodendroglial differentiation [55,56].
In vitro studies are useful to dissect these particular mecha-
nisms and allow puzzling out cell interactions and evaluating the
effects of individual factors on speciﬁc cell types. OLG-enriched
primary cultures have been extensively used as an in vitro model
of oligodendroglial maturation. More recently, NSC and NPC
biology research has become an exciting ﬁeld of study within neu-
rosciences where multipotent neural precursors can be manipu-
lated in vitro to obtain OPC-enriched primary cultures.
4. Molecules modulating myelinogenesis, demyelination and
remyelination
4.1. Galectin-3
Galectins (Gals) are a family of b-galactoside-binding lectins
lacking speciﬁc individual receptors. They bind to cell surface gly-
coconjugates containing suitable oligosaccharides to formmultiva-
lent complexes and induce intracellular signals regulating cell
survival and differentiation [57,58]. Gals also form complexes that
crosslink glycosylated ligands to form dynamic lattices (Gal–glycan
lattices, [59]). Gal-1 and -3 often have antagonistic roles in the
immunological system: while Gal-3 plays pro-inﬂammatory roles,
Gal-1 exerts anti-inﬂammatory effects [16]. Gal-3, a chimeric pro-
tein structurally composed of unusual tandem repeats of proline
and glycine-rich short segments fused onto a
carbohydrate-recognition domain (CRD), possesses multifaceted
roles in physiological processes including the regulation of innate
and adaptive immune responses [60].
Speciﬁcally in the CNS, our group was a precursor in establish-
ing the relevance of Gal–glycan lattices in OLG physiology and
identifying an essential role for Gal–glycan interactions in regulat-
ing OLG differentiation leading to the control of myelin integrity
and function (Fig. 1). Our ﬁrst ﬁndings showed a high expression
of both Gal-1 and -3 in astrocytes (AST) and MG, and an upregula-
tion of Gal-3 in differentiating OLG. This upregulation was accom-
panied by an increment in the activity of metalloproteinases
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during OLG differentiation. Interestingly, recombinant Gal-3 treat-
ment accelerated OLG differentiation in a dose- and carbohydrate-
dependent manner, which is in accordance with the
N-glycosylation proﬁle observed in immature versus differentiated
OLG. Strikingly, OPC cultured in media conditioned by
Gal-3-expressing MG produced a higher number of differentiated
OLG (myelin basic protein+ (MBP+) cells) than OPC incubated in
the presence of Gal-3-deﬁcient MG (obtained from Lgals3/ mice).
These ﬁndings received strong support from our in vivo results.
The morphometric analysis of ultrastructural studies revealed a
signiﬁcantly lower number of myelinated axons and myelin turns
(lamellae) in Lgals3/ mice. Furthermore, the g-ratio (the ratio
between the axon’s diameter and the axon’s diameter wrapped
with myelin) was observed to be higher in Lgals3/ mice, with
myelin sheaths more loosely wrapped around axons. Accompany-
ing these results, behavioral studies in Lgals3/ mice rendered
lower anxiety levels, which resembled those observed during early
CPZ-induced demyelination. Finally, neurospheres isolated from
Lgals3/ mice showed a weaker commitment to an oligoden-
droglial fate than those obtained from wild type (WT) mice
(Fig. 1). Additional ﬁndings by our group indicate that
glial-derived Gal-3, but not Gal-1, promotes oligodendroglial dif-
ferentiation. On the whole, Gal-3 contributes to myelin integrity
and function, which has critical implications in the recovery of
inﬂammatory demyelinating disorders [17].
Bibliographical evidence shows Gal-3 upregulation by inﬂam-
matory stimuli and its detrimental role in prion-infected brain
tissue [61–63]. A role for Gal-3 has also been proposed in the
negative regulation of lipopolysaccharide-induced inﬂammation
[64]. On the other hand, Gal-3 mediates the activation and
proliferation of MG-induced focal cerebral ischemia [65]. More-
over, when immunized with myelin OLG glycoprotein (MOG),
Lgals3/ mice exhibit a decrease in Experimental Autoimmune
Encephalomyelitis (EAE) severity [66]. Due to the
CPZ-mediated suppression of T cell function, the process of
demyelination and remyelination in the CPZ model can be
investigated without peripheral inﬂammation [67]. This is of
fundamental importance, as brain-intrinsic effects are difﬁcult
to separate from immune-driven ones in immune-driven
demyelination models such as EAE. CPZ-induced demyelination
increases the number of resident MG and, to a lesser extent,
peripheral macrophages [34], which have the capacity to phago-
cyte myelin debris, mostly through the upregulation of phago-
cytic receptor TREM-2b [68]. Phagocytosis of myelin debris by
MG and macrophages plays an important role in the initiation
of remyelination, as OPC differentiation can be inhibited by
myelin [69]. Myelin phagocytosis is mediated by CR3/MAC-1
and SRAI/II, which are regulated by Gal-3-dependent activation
of PI3K; as a consequence, myelin phagocytosis is deﬁcient in
Lgals3/ MG [70].
We have used a 6-week CPZ administration model in adult Lgal-
s3/ mice to evaluate the involvement of Gal-3 in the demyelina-
tion process. Although our ﬁndings showed similar susceptibility
to CPZ up to week 5 in both Lgals3/ and WT mice, OPC generated
in CPZ-treated Lgals3/ mice showed diminished arborization, a
possible sign of poor differentiating capacity. Strikingly, while
WT mice exhibited spontaneous remyelination at week 5 –even
though the demyelinating diet was still in place–, Lgals3-/- mice
exhibited continuous demyelination up to week 6, accompanied
by pronounced astroglial activation. Regarding cell response, an
increase in Gal-3 immunoreactivity during CPZ-induced demyeli-
nation was detected in MG but not in AST. Remarkably, while
CPZ-treated WT mice displayed heightened microglial activation
–as evidenced by ED1 expression– and the sharp upregulation of
phagocytic receptor TREM-2b, CPZ-demyelinated Lgals3/ miceshowed an increase in the number of caspase-3-activated
microglial cells. Behavioral studies revealed lower innate anxiety
as early as the second CPZ week in both WT and Lgals3/
mice, although only Lgals3/ mice experienced a reduction in
locomotor activity and spatial working memory. All in all, our
results indicate that Gal-3 expression in MG appears to modulate
their phenotype in response to CPZ-induced demyelination [71].
These results also show that OPC generated in response to
CPZ-induced demyelination in Lgals3/ mice have decreased abil-
ity to differentiate, which could be due to the inhibitory effects
exerted by impaired phagocytosis of myelin debris in Lgals3/
MG. Moreover, this could also be explained by our previously
informed ﬁndings demonstrating that conditioned media from
Gal-3-expressing (but not Lgals3/) MG successfully promote
OLG differentiation (Fig. 1) [17]. Previous manuscripts have
demonstrated that an interruption in OPC differentiation might
be the reason for remyelination failure [36,72,73]. Therefore, Lgal-
s3/ mice could show a delay in remyelination due to a failure in
Gal-3-induced OPC differentiation. Moreover, as Lgals3/ mice
exhibit late remyelination in an environment which is not correctly
conditioned by MG, myelin generated de novo is aberrant and
appears loosely wrapped around axons.
MG are known to release either neurotoxic or pro-recovery
factors, depending on their commitment to an M1 or M2 pheno-
type, respectively. They have been implicated in numerous
inﬂammatory processes in the brain [74,75] and have also been
proposed to take part in the initial stages of MS. The activation
and proliferation of resident MG are regulated by several factors.
In particular, Gal-3 modulates microglial response to ischemic
injury [65] and, as mentioned above, upregulates phagocytic
receptor TREM-2b during CPZ-induced demyelination (Fig. 1)
[71].
In conclusion, our results show that Gal-3 helps the myelina-
tion process by enhancing OLG differentiation and favoring oligo-
dendroglial fate following NSC differentiation [17]. The
contrasting effects of Gal-1 and Gal-3 on OLG differentiation
could be explained in the context of their anti- or
pro-inﬂammatory roles [58]. Like many cytokines and growth fac-
tors, Gals may exert a two-side effect depending on intrinsic fac-
tors including protein physicochemical properties (dimerization
or oligomerization status), stability in tissue (relative activity of
MMP), concentration and cell redox state, as well as extrinsic fac-
tors such as the glycosylation status of target cells [57,58]. In
addition, our ﬁndings demonstrate the upregulation of Gal-3 in
MG during CPZ-induced demyelination and its role in the regula-
tion of microglial activation and phenotype, hence driving the
onset of remyelination. Brieﬂy, our studies prove that Gal-3 deﬁ-
ciency leads to (1) similar vulnerability to CPZ-induced demyeli-
nation but failure in triggering spontaneous remyelination, (2) a
decrease in OPC differentiation, (3) aberrant microglial activation
during demyelination, connected to a signiﬁcant increase in the
number of proliferating MG with higher levels of CD11b and
caspase-3 activation but lacking ED1 expression, (4) microglial
inability to induce TREM-2b expression or produce TNF-a, and
(5) early behavioral alterations including lower levels of anxiety,
decreased locomotor activity and impairment in spatial working
memory [71]. Recent work has demonstrated an enhancement
in OLG differentiation in vitro with M2 cell-conditioned media
and an impairment in vivo following intra-lesional M2 cell deple-
tion, indicating an essential role for M2 cell polarization in efﬁ-
cient remyelination [76]. Therefore, Gal-3, expressed in MG,
could favor the onset of remyelination through the induction of
an M2 phenotype or a direct effect on OLG differentiation, either
extra or intracellularly. These results may thus have important
implications in the development of future therapies for a variety
of demyelinating diseases such as MS.
Fig. 1. Schematic illustration showing different effects: transferrin (Tf), galectin-3 (Gal-3) and iron on oligodendroglial cell (OLG) differentiation. Gal-3 participates in the
conversion of M1 and M2 microglial phenotypes. Gal-3, secreted by microglia (MG), induces OLG differentiation. Apotransferrin (aTf) induces OLG lineage speciﬁcation and
also favors OLG differentiation. Iron deﬁciency (ID) increases the number of oligodendroglial precursor cells (OPC) and also diminishes OLG maturation, indicating that
intrinsic OPC problems and the absence of factors secreted by astrocytes (AST) or MG affect OLG differentiation. Blue and orange arrows illustrate previously published
crosstalk between AST, MG and OPC, which positively modulate OLG maturation [45,129,130].
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Tf is the main iron carrier in the human organism and its
expression is mostly restricted to the liver. However, smaller
expression levels have been reported in OLG and choroid plexus
epithelial cells of the CNS, and in testicular sertoli cells [7,77].
Experimental models have shown the Tf molecule to play a key
role during development, with Tf-knockout mice dying shortly
after birth unless treated with an exogenous Tf source [78,79]. In
turn, lack of Tf in humans results in atransferrinemia (MIM
#209300), a rare genetic disorder characterized by microcytic ane-
mia and accumulation of excess iron in tissue, leading to body
weakness and growth delay. In the CNS, Tf has proven to be neces-
sary for myelin biosynthesis [8] and transgenic mice overexpress-
ing Tf have exhibited increased myelination [80].
Studies conducted by our group since 1994 ﬁrst found that an
intrathecal injection of Tf in postnatal day (PND) 2–5 rats induced
the expression of several myelin proteins, while an ICI of aTf in
PND-3 rats increased the levels of MBP and 20,30-cyclic-nucleotide
30-phosphodiesterase (CNPase) mRNA and protein, without affect-
ing those of proteolipid protein (PLP) [11,81–83]. Subsequently,
this ICI of aTf was found to increase the levels of tubulin and actin
mRNA, as well as various microtubule-associated proteins (MAP)
[84], although these effects occurred only when animals were
injected at PND 2–5. In turn, Tf receptor expression in in vitro
OPC was proven to become undetectable by Western blot when
cells were allowed to differentiate into mature OLG. These datasuggest the existence of a developmental time window for aTf
effectiveness [11], probably related to the loss of Tf receptor
expression in OLG, and are consistent with studies showing that
complete Tf receptor downregulation in mature OLG at PND 20
makes them no longer responsive to exogenous Tf. In vitro studies
further demonstrated that Tf addition to primary OPC cultures pro-
motes either cell migration or maturation depending on culture
conditions (Fig. 1) [85,86].
In line with these ﬁndings, Tf administration during the recov-
ery stages of CPZ demyelination was shown to reduce the
NG2-expressing cell population at the expense of an increase in
the number of APC+ cells and MBP expression, thus promoting
oligodendroglial generation and maturation [29]. Tf inhibits the
progression of OPC cycle when using an OPC culture fraction pre-
pared according to McCarthy and De Vellis [87]. This premature
cell cycle exit subsequently leads to early cell differentiation and
further favors OLG maturation [88]. In addition, similar conclu-
sions were reached in a hypoxia/ischemia experimental model of
demyelination, in terms of the positive effects of Tf on oligoden-
droglial regeneration and remyelination [89,90].
Moreover, given that NPC are potential targets for endogenous
OLG generation both in vivo and in vitro [91–93], the effects of
Tf were analyzed on rat SVZ-derived NPC cultures, with results
rendering an increase in NSC proliferation [47,94]. These data are
in line with ﬁndings described by Sergent-Tanguy et al. [95], who
demonstrated a higher expression of Tf receptor in rat embryo
NPC compared to neurons and AST cultures, and Cao et al. [96],
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(Fig. 1).
The multipotent capacity of NSC allowed us to analyze cell com-
mitment and OLG maturation in vitro as well. The exogenous
administration of Tf to NSC cultures under differentiating condi-
tions revealed an increase in OPC proportions and a shift toward
more mature OLG [94]. Guardia Clausi et al. [89] demonstrated
similar data in vivo in a model of hypoxia–ischemia where overall
myelin was restored after Tf intrathecal administration. The intra-
nasal administration of Tf was found to exert similar effects by
increasing SVZ-derived OPC numbers [90] (Fig. 1).
The effects of Tf on myelination are mediated by the functional
convergence of several signaling pathways associated with oligo-
dendrogenesis and oligodendroglial maturation [4]. In terms of
the downstream mediators acting after Tf binding to its receptor,
our studies in primary OPC cultures have demonstrated that OLG
maturation depends on Fyn kinase activation, as well as Fyn/ME-
K/ERK and PI3K/Akt pathways [97]. Further experiments using a
dominant-negative isoform of Tau to disrupt natural Tau–Fyn
interaction showed that functional Fyn is a necessary component
of OLG morphological differentiation [98]. OPC have also shown
to incorporate aTf through clathrin-AP2-mediated endocytosis,
which indicates that, during iron delivery, Tf binds to its cognate
receptors on the cell surface and enters the endosome/lysosome
canonical pathway through clathrin-coated vesicles [97].
In turn, assays performed in immortalized cell lines of the
oligodendroglial lineage at various differentiation stages [99] have
proven that the addition of aTf increases OLG morphological differ-
entiation and maturation. The stimulation of OLG differentiation
by aTf was observed to take place through the cyclic adenosine
monophosphate (cAMP)-cAMP response element-binding (CREB)
protein pathway, although CREB phosphorylation was only signif-
icant in the less mature cell line (N19). These data suggest that cell
maturational stages at least in part determine the signaling
pathways and transcription factors through which aTf induces
MBP expression. In addition, studies in these cell lines showed Tf
overexpression to promote OLG morphological complexity and
maturation [100] and to induce the expression of several genes
related to mitochondrial function and lipid metabolism, necessary
for myelin synthesis [101].
Although the precise mechanisms underlying OLG maturation
in response to Tf require further description, these results
contribute to elucidating the initial molecular events and the
transduction signals involved in oligodendrogenesis and oligoden-
droglial maturation.
4.3. Iron
Iron deﬁciency (ID) represents one of the most prevalent nutri-
tional deﬁcits, affecting almost two billion people worldwide. In
our studies, dietary ID during development was produced in preg-
nant Wistar dams by feeding them an iron-deﬁcient diet (4 mg
Fe/kg) or a control diet (40 mg Fe/kg) beginning at gestational
day 5. In contrast to the abundant evidence provided by this and
other studies on ID leading to anemia, less is known about the
impact of moderate ID on CNS development. Recently Lee et al.
[102] have established a model of non-anemic maternal ID during
gestation which generates slightly anemic ID offspring. These pups
exhibited reduced levels of brain iron and signiﬁcant age-speciﬁc
alterations in nerve conduction, but minor changes in MBP and
PLP and no changes in other myelin proteins such as
myelin-associated glycoprotein (MAG) and MOG. Whether
acquired perinatally or during early infancy, ID has detrimental
effects on brain development – including alterations in neurons
and myelination – which persist regardless of and well after iron
deﬁcits have been corrected [103–107]. Furthermore, abundantevidence suggests that early life ID anemia may impact the devel-
opment of neural systems implicated in neuropsychiatric disor-
ders, in part characterized by cognitive impairments [108,109].
OLG stain for iron more robustly that any other cell type in the
normal CNS [110]. Iron-enriched OLG usually appear in rows in
white matter, with clearly visible cell bodies and easily detectable
processes [111,112]. Among others, events involving iron
uptake and homeostasis are critical to OLG maturation and their
disruption can thus signiﬁcantly affect myelin composition and
formation.
Since the foundational work by Dallman et al. [113], ID models
have targeted different aspects of deﬁciency severity, duration and
developmental time window affected, focusing either on prenatal
or postnatal time points. In particular, developmental ID impacts
OLG maturation, causing long-lasting hypomyelination which con-
tinues in adulthood even after normal iron diet reinstatement
[15,106,114–116].
A growing body of evidence highlights two particular and rele-
vant approaches in ID: on the one hand, speciﬁc neuropathologies,
e.g. long-term deﬁcits in cognitive and socioemotional function
[117] and schizophrenia [118–121] could be modeled by ID, as
they seem to involve myelin derangement; on the other hand,
speciﬁc OLG requirements and their progression to a mature
and myelinating state correlate with environmental nutrient avail-
ability [116,122–124] and could thus also be studied through ID
models.
From a cellular point of view, studies by our group have
revealed an enlarged undifferentiated cell subpopulation in ID con-
ditions (local OPC) capable to migrate but powerless to progress
beyond this precursor stage. In other words, ID hypomyelination
does not affect cell lineage speciﬁcity but generates an arrested
OPC population. This larger number of OPC might be a homeostatic
response in order to build a complete myelin structure, the key
question being why ID local OPC remain arrested. At ﬁrst glance,
ID OPC appear to exhibit intrinsic alterations in terms of prolifera-
tion, migration and maturation (Fig. 1) [15,122].
In recent years, extensive research has exposed abundant
AST/MG interaction with OLG, which may support, limit, preclude
or drive OLG along their lineage (reviewed in Clemente et al.
[125]), in line with our results obtained in CPZ demyelination. A
positive crosstalk among AST processes, axons and OLG has been
reported in mixedmouse spinal cord cultures [126], while dynamic
changes in cell morphology and prevalence for AST differentiation
around the injection site have been demonstrated in green ﬂuores-
cent protein (GFP)-tagged neurospheres transplanted into the
spinal cord of dysmyelinated shiverer mice. Adding up to the
description of transcription factors and molecules involved in
OLG maturation [127,128], our results demonstrate that ID AST
exhibit an extended proliferative status, high basal expression of
immature markers and a diminished response capacity. In addi-
tion, ID MG display an anomalous cytokine proﬁle, not only basally
but also under stimulus (unpublished results).
On the hypothesis that deﬁciencies in OLG maturation underlie
ID, our group tested the effects of aTf on OLG differentiation in ID
animals. The sharp reduction in myelin components observed in ID
conditions at PND 24 as a sign of hypomyelination was found to be
largely prevented by an ICI of aTf at PND 3. When further exploring
the factors involved in these ameliorating effects, cultures of OLG
isolated from ID rats exhibited fewer differentiated cells relative
to controls, as evidenced by the smaller number of differentiated
MBP+ cells compared to the undifferentiated PSA-NCAM+ cells
[15]. Additional in vitro studies proved aTf administration to have
a compensatory effect on ID OLG cultures – with an increase in the
number of MBP+ cells and a decrease in the number of PSA-NCAM+
ones – and thus support in vivo ﬁndings regarding aTf effects on
OLG differentiation. In this context, the ID model becomes a
P.G. Franco et al. / FEBS Letters 589 (2015) 3388–3395 3393powerful tool to study OLG progression toward a differentiated
stage, taking into account not only OPC features and needs but also
their cellular environment and thus opening doors to new targets
in neuropathological approaches.
Altogether, our results indicate that aTf has ameliorating effects
on demyelination and hypomyelination, while Gal-3 has proven to
foster remyelination following CPZ- or LPC-induced demyelination.
These ﬁndings encourage us to search for novel therapeutic strate-
gies for the treatment of demyelinating diseases.
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